- Home
- EVRG vs PODD Comparison
EVRG vs PODD Comparison
Compare EVRG & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | PODD |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 17.0B |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EVRG | PODD |
|---|---|---|
| Price | $83.61 | $196.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | $87.25 | ★ $349.80 |
| AVG Volume (30 Days) | ★ 1.6M | 874.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.66 | 3.48 |
| Revenue | ★ $5,961,600,000.00 | $2,708,100,000.00 |
| Revenue This Year | $6.25 | $24.59 |
| Revenue Next Year | $7.18 | $19.18 |
| P/E Ratio | ★ $23.08 | $57.22 |
| Revenue Growth | 1.95 | ★ 30.73 |
| 52 Week Low | $64.75 | $197.54 |
| 52 Week High | $85.27 | $354.88 |
Technical Indicators
Market Signals| Indicator | EVRG | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 22.91 |
| Support Level | $75.04 | N/A |
| Resistance Level | $85.23 | $299.75 |
| Average True Range (ATR) | 1.23 | 6.96 |
| MACD | 0.25 | -0.67 |
| Stochastic Oscillator | 73.98 | 4.49 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission. The utility has a combined rate base of more than $20 billion, about half in Kansas and the rest split between Missouri and interstate transmission. Evergy is one of the largest wind energy suppliers in the US.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.